Pharma Manufacturing | What's Next After TrumpRx
GlaxoSmithKline and Amgen are the latest pharmaceutical giants to join the TrumpRx platform, offering direct-to-consumer medications at reduced prices while committing to massive U.S. manufacturing investments. This evolving landscape creates compelling investment opportunities in domestic drug production facilities, supply chain logistics, and digital health aggregators that help patients navigate new pricing structures.
About This Group of Stocks
Our Expert Thinking
The TrumpRx platform is reshaping how prescription drugs are priced and distributed across the United States. As pharmaceutical giants like GSK and Amgen commit to most-favoured-nation pricing and pour billions into domestic manufacturing, a ripple effect is spreading across logistics, supply chains, and digital health. This group captures that ripple — from drug makers to the companies moving and connecting those medicines to patients.
What You Need to Know
This is a thematic basket, meaning it groups companies that are all connected to the same big trend rather than a single industry. It spans global pharma developers, specialist logistics providers, and consumer-facing digital health platforms. Because it covers multiple sectors, it offers a broad lens on the shifting healthcare landscape — but as with any investment, the value of these stocks can go up as well as down.
Why These Stocks
Each stock in this group was handpicked by professional analysts to reflect a different piece of the TrumpRx story. Pharmaceutical companies are named participants or stand-out beneficiaries of domestic production incentives. Logistics firms are critical to moving medicines safely and efficiently. And digital health platforms are front and centre as patients navigate new ways to access and afford their prescriptions.
Why You'll Want to Watch These Stocks
A Once-in-a-Generation Pricing Shift
The way prescription drugs are priced in the U.S. is changing fast — and the companies at the centre of that change could be worth paying close attention to. Getting in early on a structural industry shift is exactly the kind of opportunity long-term investors look for.
Billions Being Poured Into U.S. Soil
Major pharmaceutical companies are pledging enormous capital investments into domestic manufacturing — and the logistics and supply chain firms supporting that build-out could see serious tailwinds. This is industrial-scale momentum that analysts are actively tracking.
Digital Health Is Having Its Moment
As patients search for cheaper, more accessible medications, digital health platforms and prescription savings apps are seeing surging demand. Companies like GoodRx, Hims & Hers, and Teladoc sit right at the intersection of tech and healthcare — a space that experts believe is only going to grow.
